Association Between Off‐Label Use of Cardio‐Kidney‐Metabolic Therapies and Risk of Cardiovascular Events in Type 1 Diabetes: A Real‐World Evidence Study

A.P. has received grant funding (to the institution) from NHLBI, AHA, Roche, Ultromics, Astra Zeneca; has recieved honoraria outside of the present work as a consultant, advisor, or speaker from Tricog, Elli Lilly, Bayer, Astra Zeneca, Rivus, Roche, Axon Therapies, Novo Nrodisk, Merck, Abbott, Edwards Lifesciences, Anumana, MedicalAI, Science37, Kardigan, Antlia Biosciences, Kieele Health, Novartis, iRhythm, Sarfez Pharma, Boehringer Ingelheim, BSWRI, Tenax Pharma, Alnylam, and Vasa Theraputics. E.R. and C.P. report being employees of Roche Corporation during the period of study. M.L.C. reports recieving grant funding (to the institution) from Bayer and Elli Lilly; ha served as a consultant for and/or recieved honoraria outside of the present study as an advisor/consultant from Abbott, Armana Theraputics, Bayer AG, Bayer Theraputics, and Novo Nordisk; has recieved grant funding for research from NIDDK (R01DK1210191, U01DK133097), and Breakthrough T1D (formerly JDRF; JDRF 5-SRA-2024-1471-M-B). The other authors declare no conflicts of interest. The data are commercially available from Optum for a fee. The peer review history for this article is available at https://www.webofscience.com/api/gateway/wos/peer-review/10.1111/dom.70597.